Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.274, 2000-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
IFN- -2b + ribavirin preferred initial treatment for hep C
Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. :
Access to resources
Recommend
IFN- -2b + ribavirin + amantadine for treatment-resistant hepatitis C
Inpharma, Vol. 1, Iss. 1388, 2003-01 ,pp. :
Peginterferon-α-2b + ribavirin for hep C during methadone treatment
Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. :
PEG IFN- -2b + weight-based ribavirin best value in hep C
Inpharma, Vol. 1, Iss. 1386, 2003-01 ,pp. :
IFN- -2b + ribavirin more cost effective in hepatitis C
Inpharma, Vol. 1, Iss. 1307, 2001-01 ,pp. :